4.7 Article

Regulation of Inflammation-Mediated Endothelial to Mesenchymal Transition with Echinochrome a for Improving Myocardial Dysfunction

Journal

MARINE DRUGS
Volume 20, Issue 12, Pages -

Publisher

MDPI
DOI: 10.3390/md20120756

Keywords

endothelial-mesenchymal transition; echinochrome A; myocardial infarction; cardiac fibrosis

Funding

  1. National Research Foundation of Korea (NRF) - Korean government (MSIT) [2021R1F1A1057427, 2020R1A4A1019322]
  2. Bio and Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science and ICT [2017M3A9G7072568]
  3. National Research Foundation of Korea [2017M3A9G7072568, 2020R1A4A1019322, 2021R1F1A1057427] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Endothelial-mesenchymal transition (EndMT) is a process in which endothelial cells transition into mesenchymal cells and induce fibrosis due to ischemic conditions in the heart. In this study, echinochrome A (EchA) was found to negatively regulate EndMT and reduce fibrosis in the myocardium. It was also shown to have anti-inflammatory and antioxidant effects, as well as improve mitochondrial dysfunction. Animal experiments confirmed the control of EndMT by EchA.
Endothelial-mesenchymal transition (EndMT) is a process by which endothelial cells (ECs) transition into mesenchymal cells (e.g., myofibroblasts and smooth muscle cells) and induce fibrosis of cells/tissues, due to ischemic conditions in the heart. Previously, we reported that echinochrome A (EchA) derived from sea urchin shells can modulate cardiovascular disease by promoting anti-inflammatory and antioxidant activity; however, the mechanism underlying these effects was unclear. We investigated the role of EchA in the EndMT process by treating human umbilical vein ECs (HUVECs) with TGF-beta 2 and IL-1 beta, and confirmed the regulation of cell migration, inflammatory, oxidative responses and mitochondrial dysfunction. Moreover, we developed an EndMT-induced myocardial infarction (MI) model to investigate the effect of EchA in vivo. After EchA was administered once a day for a total of 3 days, the histological and functional improvement of the myocardium was investigated to confirm the control of the EndMT. We concluded that EchA negatively regulates early or inflammation-related EndMT and reduces the myofibroblast proportion and fibrosis area, meaning that it may be a potential therapy for cardiac regeneration or cardioprotection from scar formation and cardiac fibrosis due to tissue granulation. Our findings encourage the study of marine bioactive compounds for the discovery of new therapeutics for recovering ischemic cardiac injuries.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available